Boxer Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Boxer Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.63M	Hold	749,035	–	–	0.27%	46
2026 Q1	$2.56M	Buy	+749,035	New	+$1.55M	0.34%	41

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Boxer Capital Management's ANTX Position: Q2 2026 in Review

Boxer Capital Management held its AN2 Therapeutics (ANTX) position steady in Q2 2026 at 749,035 shares worth $3.63M. The position accounts for 0.27% of the portfolio, ranked #46.

Boxer Capital Management first reported a position in ANTX in Q1 2026 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Boxer Capital Management held 749,035 shares of AN2 Therapeutics worth $3.63M as of Q2 2026.
Boxer Capital Management left its AN2 Therapeutics share count unchanged in Q2 2026.
AN2 Therapeutics made up 0.27% of Boxer Capital Management's portfolio in Q2 2026, its #46 holding.
Boxer Capital Management first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 2 quarters since.
59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.